The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 37 | — | 20.1x | Near average | |
Growth | 1 | — | 5.6% | Below average | |
Quality | 1 | -969.0% | 7.6% | Below average | |
Safety | 36 | 0.0x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | 62 | — | — | Near average | |
Sentiment | 4 | — | — | Below average |
Sensei Biotherapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Sensei Biotherapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
SNSE stock has witnessed a radical shift in analyst expectations over the past week, as the consensus target price jumped from $5.5 to $50, an exceptional increase of 809%. This change is primarily due to a comprehensive re-evaluation and new coverage from major institutions such as Cantor Fitzgerald with an 'Overweight' rating, reflecting excessive optimism despite continued expectations of losses in earnings per share (EPS) for the coming fiscal years.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.